Learn More
BACKGROUND Lowering LDL cholesterol with statin regimens reduces the risk of myocardial infarction, ischaemic stroke, and the need for coronary revascularisation in people without kidney disease, but its effects in people with moderate-to-severe kidney disease are uncertain. The SHARP trial aimed to assess the efficacy and safety of the combination of(More)
AIMS Niacin has potentially favourable effects on lipids, but its effect on cardiovascular outcomes is uncertain. HPS2-THRIVE is a large randomized trial assessing the effects of extended release (ER) niacin in patients at high risk of vascular events. METHODS AND RESULTS Prior to randomization, 42 424 patients with occlusive arterial disease were given(More)
INTRODUCTION Lamotrigine is licensed in many countries for use in patients with partial seizures. Evidence suggests that it may also be effective in generalised epilepsies. MATERIAL & METHODS We analysed retrospectively our patients with idiopathic generalised epilepsy with refractory absences. RESULTS Fifteen patients with idiopathic generalised(More)
BACKGROUND The absolute and relative importance of smoking to vascular and nonvascular outcomes in people with chronic kidney disease (CKD), as well its relevance to kidney disease progression, is uncertain. STUDY DESIGN Observational study. SETTING & PARTICIPANTS 9,270 participants with CKD enrolled in SHARP. PREDICTOR Baseline smoking status(More)
  • 1